Drug intelligence / Profile preview

DN1406131

Development stage: Phase 1
Lead developer: Shanghai De Novo Pharmatech
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

DN1406131 is a selective, orally administered small molecule dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2). Both IDO1 and TDO2 catalyze the first and rate-limiting step in the conversion of tryptophan to kynurenine. By inhibiting these enzymes, DN1406131 blocks production of kynurenine—a ligand for the aryl hydrocarbon receptor (AhR)—thereby disrupting an immunosuppressive pathway that tumors exploit to evade immune surveillance. The drug is being developed primarily as an antineoplastic agent for solid tumors[1][2][3].

Targets

TDO2 (Tryptophan 2,3-dioxygenase)IDO1 (Indoleamine 2,3-dioxygenase 1)

Beyond the preview

Go deeper on DN1406131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DN1406131.

Explore the full profile